Cytek Biosciences Inc
NASDAQ:CTKB

Watchlist Manager
Cytek Biosciences Inc Logo
Cytek Biosciences Inc
NASDAQ:CTKB
Watchlist
Price: 4.01 USD 0.25% Market Closed
Market Cap: $512.7m

Intrinsic Value

The intrinsic value of one CTKB stock under the Base Case scenario is hidden USD. Compared to the current market price of 4.01 USD, Cytek Biosciences Inc is hidden .

CTKB Intrinsic Value
HIDDEN
Show

Valuation History
Cytek Biosciences Inc

Intrinsic Value History
Dive into the past to invest in the future

CTKB looks overvalued. Yet it might still be cheap by its own standards. Some stocks live permanently above intrinsic value; Historical Valuation reveals whether CTKB usually does or if today's premium is unusual.

Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Show Historical Valuation
What is Valuation History?
Ask AI Assistant
What other research platforms think about CTKB?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is CTKB valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Cytek Biosciences Inc.

Explain Valuation
Alternatives to CTKB

Fundamental Analysis

Financials
Efficiency

Earnings Waterfall
Cytek Biosciences Inc

Wall St
Price Targets

Dividends

Cytek Biosciences Inc
does not pay dividends
Shareholder Yield
Buyback Yield
HIDDEN
Debt Paydown Yield
HIDDEN

Competitive Landscape

Ownership

CTKB Insider Trading
Buy and sell transactions by insiders

CTKB News

What is the Intrinsic Value of one CTKB stock?

The intrinsic value of one CTKB stock under the Base Case scenario is hidden USD.

Is CTKB stock undervalued or overvalued?

Compared to the current market price of 4.01 USD, Cytek Biosciences Inc is hidden .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett